Cart
sales@molnova.com
XY028-140
CAS No. 2229974-83-6
XY028-140( —— )
Catalog No. M28083 CAS No. 2229974-83-6
XY028-140 is a selective CDK4/CDK6 degrade and inhibits both CDK4/6 expression and activity in cancer cells. XY028-140 is a PROTAC connected by ligands for Cereblon and CDK.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 76 | In Stock |
|
| 10MG | 122 | In Stock |
|
| 25MG | 250 | In Stock |
|
| 50MG | 392 | In Stock |
|
| 100MG | 584 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameXY028-140
-
NoteResearch use only, not for human use.
-
Brief DescriptionXY028-140 is a selective CDK4/CDK6 degrade and inhibits both CDK4/6 expression and activity in cancer cells. XY028-140 is a PROTAC connected by ligands for Cereblon and CDK.
-
DescriptionXY028-140 is a selective CDK4/CDK6 degrade and inhibits both CDK4/6 expression and activity in cancer cells. XY028-140 is a PROTAC connected by ligands for Cereblon and CDK.(In Vitro):In A375 melanoma and T47D breast cancer cells, XY028-140(0.3 or 1 μΜ for 24h) inhibited both CDK4/6 expression and CDK4/6 activity. In T47D breast cancer cells, XY028-140(0.03, 0.1, 0.3, 1, or 3 μΜ for 11d) inhibited cancer cell proliferation in breast cancer cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorEndogenous Metabolite|Apoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2229974-83-6
-
Formula Weight760.8
-
Molecular FormulaC39H40N10O7
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 5.56 mg/mL (7.31 mM)
-
SMILESN/A
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Leung HW, et al. The natural agent 4-vinylphenol targets metastasis and stemness features in breast cancer stem-like cells. Cancer Chemother Pharmacol. 2018 Aug;82(2):185-197.
molnova catalog
related products
-
CK7
CK7, a?Cdk2/9?inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.
-
CDK9-IN-2
CDK9-IN-2 is a potent and selective CDK9 inhibitor with IC50 of <8 nM, example 4 in patent WO2011026917A1.
-
CDK5 inhibitor 20-22...
CDK5 inhibitor 20-223 (CP 668863) potent, selective, ATP-competitive CDK2/5 inhibitor with IC50 of 6.0 and 8.8 nM for CDK2/CyclinE and CDK5/p35, with little to no activity against CDK1/4/6/7/9.
